Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.

The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response.

Study hypothesis The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maastricht Radiation Oncology

Criteria

Inclusion Criteria:

• Histological proven rectal cancer

• UICC stage I-IV

• WHO performance status 0-2

• Less than 10 % weight loss in the last 6 months

• In case of previous chemotherapy, radiotherapy can start after a minimum of 21 days after the last chemotherapy course

• No recent (< 3 months) severe cardiac disease (arrhythmia, congestive heart failure,infarction)

• Life expectancy more than 6 months

• Measurable cancer

• Willing and able to comply with the study prescriptions

• 18 years or older

• Not pregnant and willing to take adequate contraceptive measures during the study

• Have given written informed consent before patient registration

• No previous radiotherapy to the pelvis

Exclusion Criteria:

• Not adenocarcinoma histology

• History of prior pelvis radiotherapy

• Recent (< 3 months) myocardial infarction

• Uncontrolled infectious disease

• Less than 18 years old

• Pregnant or not willing to take adequate contraceptive measures during the study